Skip to main content

Table 1 Characteristics of included trials

From: High-flow oxygen via nasal cannulae in patients with acute hypoxemic respiratory failure: a systematic review and meta-analysis

Trial Total (n), HFNC/control Setting Severity of illness score Intervention protocol Control protocol Protocol duration Longest follow-up
Frat 2015 [26] 106/207 Medical and surgical ICU SAPS II; HFNC 25 ± 9, standard 24 ± 9, NIV 27 ± 9 HFNC Standard oxygen arm and NIV arm Recovery or intubation 90 days
Jones 2016 [34] 172/150 Emergency Department NR HFNC standard oxygen Recovery or admission 90 days
Lemiale 2015 [29] 53/49 Immuno-compromised ICU SAPS II; HFNC 42 (29.5–52), control 37.5 (31.5–46.5) HFNC Standard oxygen venturi mask 120 min ICU stay
Rittayamai 2015 [30] 20/20 Emergency department NR HFNC Standard oxygen ED stay 60 min
Simon 2014 [31] 20/20 Medical and surgical ICU SAPS II; HFNC 43 ± 13, control 46 ± 10 HFNC NIV 15 min pre-, 50 min post-bronchoscopy 28 days
Stephan 2015 [27] 414/416 Post-cardiac surgery ICU SAPS II; HFNC 29 (27.8–30.1), control 28.8 (27.7–30.0) HFNC NIV NR ICU stay
Vourc’h 2015 [28] 63/61 Medical and surgical ICU SAPS II; HFNC 54.5 ± 20.2, control 51.3 ± 16.5 HFNC Face mask 4 min + 28 days
  1. HFNC high-flow nasal cannulae, NR not reported, ICU intensive care unit, ED emergency department, NIV non-invasive ventilation, SAPS Simplified Acute Physiology Score